Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
Pharmaceutical Investing Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
Pharmaceutical Investing Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
Medical Device Investing Abiomed Announces European Approval (CE Marking) for Impella 5.5 and First Patient Treated at University Heart Center Hamburg
Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial
Pharmaceutical Investing BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema
Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy
Pharmaceutical Investing BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma
